BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets

April 10, 2017

With the Latin American vaccines market forecast to more than quadruple in size from just over USD 150 million to 2015 to just under USD 700 million in 2020, opportunities abound for both homegrown businesses and multinationals looking to tap into local markets. Fernando Lobos, business development director of Sinergium Biotech, an Argentine biopharmaceutical company specializing in the research, development, production and marketing of vaccines and highly complex biopharmaceuticals, revealed to Scrip’s Mike Ward, how the company can be a gateway to the Latin American market for both multinationals and smaller biotechs. Sinerguim has one manufacturing plant in operation and another one under construction. It has already signed deals with Novartis, to supply vaccines that can combat various influenza strains; Merck Sharp & Dohme for the production of its tetravalent vaccine against HPV; and Pfizer for the production of its pneumococcal conjugate vaccine. Last year, the company entered into an agreement with Protein Sciences Corporation and Mundo Sano for the joint development of a vaccine against the Zika virus.

 

 

Click here for more coverage of the activities held during BIO-Europe Spring

 

Previous Video
BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs
BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs

Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s M...

Next Article
Tissue regeneration: A vital area within regenerative medicine
Tissue regeneration: A vital area within regenerative medicine

Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence an...